Exelixis, Inc. - Common Stock (NQ:EXEL)

58.42 +0.03 (+0.06%)

Delayed Quote Updated: 9:57 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Biotech Leader Exelixis Pops After Obliterating First-Quarter Profit Expectations ↗

May 13, 2025

The top-notch biotech company easily beat first-quarter profit expectations.

Via Investor's Business Daily

Topics Stocks

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025

From Exelixis, Inc.

Via Business Wire

Exploring Exelixis's Earnings Expectations ↗

May 12, 2025

Via Benzinga

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

May 07, 2025

From Exelixis, Inc.

Via Business Wire

Is the Market Bullish or Bearish on Exelixis? ↗

April 29, 2025

Via Benzinga

Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock. ↗

March 10, 2025

A fundamental and technical analysis of (NASDAQ:EXEL): EXELIXIS INC (NASDAQ:EXEL) may be suited for high growth investing, we'll explore why in this article.

Via Chartmill

Peering Into Exelixis's Recent Short Interest ↗

March 03, 2025

Via Benzinga

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL) – A Strong Minervini Trend Template Candidate ↗

May 01, 2025

EXELIXIS INC (NASDAQ:EXEL) – A Strong Minervini Trend Template Candidate

Via Chartmill

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

April 29, 2025

From Exelixis, Inc.

Via Business Wire

For those who appreciate growth without the sticker shock, EXELIXIS INC (NASDAQ:EXEL) is worth considering. ↗

April 28, 2025

Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing...

Via Chartmill

Does EXELIXIS INC (NASDAQ:EXEL) align with Mark Minervini’s trading strategy? ↗

April 25, 2025

A fundamental and technical analysis of (NASDAQ:EXEL): Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock.

Via Chartmill

Expert Outlook: Exelixis Through The Eyes Of 19 Analysts ↗

April 17, 2025

Via Benzinga

Why EXELIXIS INC (NASDAQ:EXEL) is Poised for High Growth. ↗

April 16, 2025

Exploring high growth characteristics of EXELIXIS INC (NASDAQ:EXEL). A fundamental and technical analysis of (NASDAQ:EXEL).

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock and is consolidating. ↗

April 14, 2025

Based on a technical and fundamental analysis of NASDAQ:EXEL we can say: EXELIXIS INC (NASDAQ:EXEL), a strong growth stock, setting up for a breakout.

Via Chartmill

For those who appreciate growth without the sticker shock, EXELIXIS INC (NASDAQ:EXEL) is worth considering. ↗

April 05, 2025

EXELIXIS INC was identified as a growth stock that isn't overvalued. NASDAQ:EXEL is excelling in various growth indicators while maintaining a solid financial footing.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) stands out as a stock that provides good value for the fundamentals it showcases. ↗

April 03, 2025

EXELIXIS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:EXEL showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

The Smartest Biotech Stocks to Buy With $50 ↗

April 03, 2025

Via The Motley Fool

FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors ↗

March 26, 2025

Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival benefits in renal cancer.

Via Benzinga

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

March 26, 2025

From Exelixis, Inc.

Via Business Wire

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

March 25, 2025

From Exelixis, Inc.

Via Business Wire

Looking Into Exelixis's Recent Short Interest ↗

March 25, 2025

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL)—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗

March 22, 2025

Based on a technical and fundamental analysis of NASDAQ:EXEL we conclude: EXELIXIS INC (NASDAQ:EXEL)—A High-Growth Stock Gearing Up for Its Next Upward Move.

Via Chartmill

What 25 Analyst Ratings Have To Say About Exelixis ↗

March 13, 2025

Via Benzinga

Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation. ↗

March 13, 2025

Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing...

Via Chartmill

Is This The Beginning? Insights On Bearish Distribution Patterns ↗

March 12, 2025

Discover the characteristics of a bearish distribution and the criteria the S&P 500 needs for a technical rally.

Via Talk Markets

Topics Stocks Stocks / Equities

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

February 25, 2025

From Exelixis, Inc.

Via Business Wire

This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

February 24, 2025

Via Benzinga

Why Exelixis Stock Trounced the Market on Thursday ↗

February 21, 2025

Via The Motley Fool

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? ↗

February 21, 2025

Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.